Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Bribery serves as life-support for Chinese hospitals

Tue, 23rd Jul 2013 21:00

* Low salaries foster widespread bribery in public hospitals

* State fixes cost of hospital operations and caps drugprices

* Leaves public hospitals with little room to top updoctors' pay

* Britain's GlaxoSmithKline embroiled in bribery scandal

By Kazunori Takada

SHANGHAI, July 24 (Reuters) - Bribery is the lubricant thathelps keep China's public hospitals running, and the healthsystem would struggle to function without illegal payments topoorly paid doctors and administrators, say medicalpractitioners and industry experts.

They say government policies are partly to blame for asystem in which doctors and other staff expect to be paid extrafees to perform operations and take kickbacks frompharmaceutical firms and medical-equipment suppliers.

The profession's ugly underbelly was exposed last week whenpolice accused British drugmaker GlaxoSmithKline ofbribing officials and doctors for six years to boost sales andthe price of its medicines. GSK has called the developments"shameful" and on Monday said some of its Chinese executivesappeared to have broken the law.

China is an appealing market for pharmaceutical firms andmedical-equipment makers, with spending in the industry expectedto nearly triple to $1 trillion by 2020 from $357 billion in2011, according to consulting firm McKinsey.

The corruption stems largely from doctors' low basesalaries, which are set in line with a pay scale for governmentworkers. Hospitals can pay bonuses but, given public hospitalsare strapped for cash, compensation is usually low, say doctorsand industry experts.

A doctor fresh out of medical school in Beijing earns about3,000 yuan ($490) a month including bonuses -- roughly the sameas a taxi driver. A doctor with 10 years experience makes around10,000 yuan a month, according to Peter Chen, chief executive ofprivately run Oasis International Hospital in Beijing.

"Without the grey income, doctors would not have theincentive to practise," said Yanzhong Huang, a senior fellow forglobal health at the Council on Foreign Relations in New York.

CAN'T SURVIVE ON SALARIES

Over the past 30 years the Chinese government has made itshealthcare sector more market-oriented. That means the country's 13,500 public hospitals have to balance their own books.

Medical services accounted for just over 50 percent ofpublic hospital revenue in 2011, according to Health Ministrydata. About 40 percent came from prescribing drugs while therest was from other income as well as government subsidies,which have fallen steadily since the 1980s.

Hospital administrators can set fees for in-patient care,nursing and laboratory tests. But the state fixes the cost ofoperations to make surgery affordable to ordinary Chinese. Andit effectively caps the cost of many prescribed medicines bysetting a suggested price.

That leaves hospitals little room to top up wages.

One Chinese doctor who used to hold a senior position at aprominent hospital in Beijing said 80 percent of his income camefrom bribes. Without it, he would have earned less than $600 amonth, said the doctor, who left China five years ago to live inBritain where he continues practising medicine.

"These sums (bribes) are essential. You cannot survive onyour salary," said the 50-year-old physician, who spoke oncondition of anonymity due to the sensitivity of the issue.

An industry executive who has worked in China's medicalsector for more than 15 years said bribery and corruptionpermeated every level of a public hospital.

"They are seen as necessities in the current healthcaresystem," said the executive, who also declined to be identified.

The Health Ministry did not respond to a request forcomment. Officials at the National Development and ReformCommission, which sets the prices of prescribed medicines, alsodeclined to comment.

Low base salaries are a legacy of China's planned economy,said Jia Xijin, associate professor at the School of PublicPolicy and Management at Tsinghua University in Beijing,explaining the dilemma faced by the government.

China has also committed to making health care affordablefor its 1.37 billion people. The government has spent 2.2trillion yuan ($358 billion) on the system since 2009, of whichmore than 680 billion yuan was to provide universal healthinsurance coverage, state media quoted the Finance Ministry assaying earlier this year.

RED ENVELOPES

Public hospitals say recruiting new doctors is gettingharder as many physicians are turned off by the wages at a timewhen patient numbers are growing. Health Ministry data showedthe overall number of doctors rose 13 percent from 2008 to 2011,while patient visits jumped 28 percent.

"There will be no doctors left to treat the current doctorswhen they retire," said the accounting director at a Shanghaihospital who declined to be identified because she was notauthorised to speak to the media.

Low salaries have also spawned a system of under-the-tablepayments from patients. The payments are known as "hongbao" -- areference to the cash-filled red envelopes given as presentsduring Lunar New Year festivities -- and cover various servicesfrom jumping the queue for appointments to extra surgical fees.

Bob Wang, a 35-year-old businessman in Beijing, said he gavethe main surgeon who operated on his aunt's femur bonetransplant last year 5,000 yuan in "hongbao" on top of the100,000 yuan he paid to the hospital because he was worried thedoctor would not take the operation seriously otherwise.

There was unstated "hongbao" guidance for each type ofsurgery, he said.

"If my family or myself get sick ... we won't just go to thehospital. Everything will take forever -- from registration towaiting for a bed, to getting seen by a doctor to queuing forsurgery," he said.

According to the doctor now living in Britain, patients andtheir families could sometimes spend two to three times morethan the actual fee in "hongbao".

Critics doubt that an anti-corruption campaign by PresidentXi Jinping will have much impact.

Indeed, a former doctor at a major heart hospital in Beijingsaid eradicating corruption would be nearly impossible.

"It would be easy to find out who was taking money if thegovernment wanted to," said the cardiologist, who has beenworking in the United States since 2009.

"But everyone would be found guilty. How could the hospitalssurvive?"

More News
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.